Neurocognition after stereotactic radiosurgery for brain metastases
Research type
Research Study
Full title
Neurocognitive and quality of life outcomes after stereotactic radiosurgery for brain metastases
IRAS ID
239459
Contact name
Poulam Patel
Contact email
Sponsor organisation
The University of Nottingham
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Stereotactic radiosurgery (SRS) is a form of high dose, high precision radiotherapy. This can be administered to patients with limited volume brain metastases with the intention of long term control. SRS avoids the risk of neurosurgery or toxicitiy from whole brain radiotherapy. Nottingham University Hospitals has been commissioned by NHS England to provide and improve patient access to this service. The catchment area is the East Midlands.
Patients with brain metastases are surviving longer, due to improvement in systemic anti-cancer treatment. This also means that patients now living long enough to potentially develop the late toxicities, such as memory loss and concentration problems, from SRS. There is scant data on long term neurocognitive and quality of life outcomes following SRS
The intention of this research is
1. To use neurocognitive assessment tool to assess neurocognitive and quality of life outcomes following SRS
2. Investigate the relationship the above outcomes and dosimetric and radiotherapy data
The study site is Nottingham City Hospital. The study population are patients who are clinically eligible for SRS. Prospective participants will be recruited in outpatient clinic. The entire study is expected to run over 2 years. If the patient consents to participation, baseline neurocognitive and quality of life assessment, using task-based tests and questionnaires, will be conducted. The patient will then undergo SRS. Following SRS the patient will be followed-up clinically and radiologically with repeat MRI head; this is normal clinical practice. During these follow-ups, repeat neurocognitive and quality of life assessments will be conducted as part of the research. The relationship between neurocognition and quality of life and other factors (as described above) will be investigated. Follow-up will cease at death (the median survival for patients with brain metastases is 12 months), or if the patient becomes to unwell to attend, or withdraws consent.REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
18/WM/0178
Date of REC Opinion
10 Sep 2018
REC opinion
Further Information Favourable Opinion